Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin

Phase 2 Completed 20 enrolled Johns Hopkins University Duke University · collab Pfizer · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary objective is to assess the efficacy, safety, and tolerability of Abrocitinib for the treatment of Prurigo Nodularis (PN) or Chronic Pruritus of Unknown Origin (CPUO) in patients experiencing moderate to severe pruritus.

Timeline

Start: 2021-09-09
Primary completion: 2022-07-11
Completion: 2022-07-11

Outcome

Met primary endpoint

paper PP-NRS scores decreased by 78.3% in PN (95% CI, -118.5 to -38.1; P < .001) PMID 38837144 ↗

registry analysis (superiority test); Chronic Pruritus of Unknown Origin; p = 0.0142; Mean Difference (Net) 53.66 (95% CI 8.55 to 98.76); ANOVA; note: Threshold of significance at 0.05. NCT05038982 ↗

Publications

Kwatra SG, Bordeaux ZA, Parthasarathy V, Kollhoff AL, Alajmi A, Pritchard T, Cornman HL, Kambala A, Lee KK, Manjunath J, Ma EZ, Dillen C, Kwatra MM. Efficacy and Safety of Abrocitinib in Prurigo Nodularis and Chronic Pruritus of Unknown Origin: A Nonrandomized Controlled Trial. JAMA Dermatol. 2024 Jul 1;160(7):717-724. doi: 10.1001/jamadermatol.2024.1464.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abrocitinib	Small molecule	200 mg	Oral